全文获取类型
收费全文 | 2613篇 |
免费 | 252篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 28篇 |
儿科学 | 127篇 |
妇产科学 | 37篇 |
基础医学 | 339篇 |
口腔科学 | 19篇 |
临床医学 | 339篇 |
内科学 | 423篇 |
皮肤病学 | 49篇 |
神经病学 | 302篇 |
特种医学 | 80篇 |
外国民族医学 | 1篇 |
外科学 | 335篇 |
综合类 | 12篇 |
一般理论 | 3篇 |
预防医学 | 415篇 |
眼科学 | 30篇 |
药学 | 145篇 |
中国医学 | 4篇 |
肿瘤学 | 182篇 |
出版年
2024年 | 10篇 |
2023年 | 35篇 |
2022年 | 68篇 |
2021年 | 167篇 |
2020年 | 128篇 |
2019年 | 148篇 |
2018年 | 149篇 |
2017年 | 114篇 |
2016年 | 103篇 |
2015年 | 130篇 |
2014年 | 119篇 |
2013年 | 179篇 |
2012年 | 260篇 |
2011年 | 188篇 |
2010年 | 109篇 |
2009年 | 96篇 |
2008年 | 140篇 |
2007年 | 115篇 |
2006年 | 105篇 |
2005年 | 94篇 |
2004年 | 70篇 |
2003年 | 66篇 |
2002年 | 44篇 |
2001年 | 15篇 |
2000年 | 15篇 |
1999年 | 24篇 |
1998年 | 7篇 |
1996年 | 7篇 |
1993年 | 8篇 |
1992年 | 14篇 |
1991年 | 11篇 |
1990年 | 8篇 |
1989年 | 14篇 |
1988年 | 12篇 |
1987年 | 9篇 |
1986年 | 14篇 |
1985年 | 9篇 |
1984年 | 10篇 |
1983年 | 7篇 |
1981年 | 3篇 |
1980年 | 3篇 |
1977年 | 3篇 |
1976年 | 3篇 |
1973年 | 2篇 |
1972年 | 2篇 |
1968年 | 2篇 |
1966年 | 2篇 |
1956年 | 2篇 |
1890年 | 7篇 |
1889年 | 7篇 |
排序方式: 共有2870条查询结果,搜索用时 31 毫秒
101.
102.
Meghan Milburn MD Martin Rosman MD Charles Mylander PhD Lorraine Tafra MD FACS 《The breast journal》2013,19(4):357-364
Oncotype DX has been criticized for not providing significantly more prognostic information than histopathologic analysis. Oncotype DX was validated in cohorts that included poor prognostic factors (HER2‐positive, low‐estrogen receptor [ER] expression), raising the question: if patients with known high recurrence rates are excluded, is the Recurrence Score (RS) still valid? Our purpose was to determine if RS can be predicted with readily available measures. One hundred and twenty samples from August 2006 to November 2010 that underwent Oncotype DX testing were analyzed. Data included RS, ER, progesterone receptor (PR), HER2, and Ki67 status by immunohistochemistry (IHC). IHC data were used to create two linear regression models to predict RS. SAS's JMP‐7 was used for statistical analysis. When comparing Oncotype DX‐ and IHC‐derived ER and PR values, there were 21 discordant samples. The linear regression model PRS‐F created with IHC data (ER, PR, HER2, Ki67) from all samples (n = 120) had an adjusted R2 = 0.60 indicating a good model for predicting RS. The PRS‐R model was built without low‐ER and HER2‐positive samples (n = 110). It had an adjusted R2 = 0.38 indicating poor prediction of RS. Oncotype DX data showed good concordance with IHC for ER‐ and PR‐expression in this cohort. Low‐ER samples had high RS. After removing low‐ER and HER2‐positives, calculating RS with PRS‐R from remaining data showed poor predictive power for RS (adjusted R2 = 0.38). This result questions whether RS is prognostic in this subgroup (who would most benefit from further clarification of recurrence risk) and independent of pathology, or is simply producing random RS values. Data bases available to Genomic Health can resolve this issue. 相似文献
103.
Martin M. Mortazavi Meghan Denning Bulent Yalcin Mohammadali M. Shoja Marios Loukas R. Shane Tubbs 《Child's nervous system》2013,29(7):1073-1078
Introduction
The intracranial bridging veins are pathways crucial for venous drainage of the brain. They are not only involved in pathological conditions but also serve as important landmarks within neurological surgery.Methods
The medical literature on bridging veins was reviewed in regard to their historical aspects, embryology, histology, anatomy, and surgery.Conclusion
Knowledge on the intracranial bridging veins and their dynamics has evolved over time and is of great significance to the neurosurgeon. 相似文献104.
Kazuko Sakata Joshua R. Mastin Sean M. Duke Meghan G. Vail Abigail E. Overacre Brittany E. Dong Shanker Jha 《The European journal of neuroscience》2013,37(11):1863-1874
Brain‐derived neurotrophic factor (BDNF) is implicated in the pathophysiology of major depression; mice lacking BDNF expression through promoter IV (BDNF‐KIV) exhibit a depression‐like phenotype. We tested our hypothesis that deficits caused by promoter IV deficiency (depression‐like behavior, decreased levels of BDNF, and neurogenesis in the hippocampus) could be rescued by a 3‐week treatment with different types of antidepressants: fluoxetine, phenelzine, duloxetine, or imipramine. Each antidepressant reduced immobility time in the tail suspension test without affecting locomotor activity in the open field test in both BDNF‐KIV and control wild type mice, except that phenelzine increased locomotor activity in wild type mice and anxiety‐like behavior in BDNF‐KIV mice. The antidepressant treatments were insufficient to reverse decreased BDNF levels caused by promoter IV deficiency. No antidepressant treatment increased the hippocampal progenitors of either genotype, whereas phenelzine decreased the surviving progenitors in both genotypes. The antidepressant treatments differently affected the dendritic extension of hippocampal immature neurons: fluoxetine and imipramine increased extension in both genotypes, duloxetine increased it only in BDNF‐KIV mice, and phenelzine decreased it only in wild type mice. Interestingly, a saline‐only injection increased neurogenesis and dendrite extensions in both genotypes. Our results indicate that the behavioral effects in the tail suspension test by antidepressants do not require promoter IV‐driven BDNF expression and occur without a detectable increase in hippocampal BDNF levels and neurogenesis but may involve increased dendritic reorganisation of immature neurons. In conclusion, the antidepressant treatment demonstrated limited efficacy; it partially reversed the defective phenotypes caused by promoter IV deficiency but not hippocampal BDNF levels. 相似文献
105.
106.
Mitchell Lorena Wilkosz Meghan Fuehrlein Brian 《Community mental health journal》2022,58(7):1381-1384
Community Mental Health Journal - Psychiatric Emergency Services (PES) at Connecticut Department of Veterans Affairs (VACT) began offering the COVID-19 vaccine to eligible veterans in February... 相似文献
107.
Meghan H. Pearl Anjali B. Nayak Robert B. Ettenger Dechu Puliyanda Miguel Fernando Palma Diaz Qiuheng Zhang Elaine F. Reed Eileen W. Tsai 《Pediatric nephrology (Berlin, Germany)》2016,31(8):1341-1348
Background
Current therapeutic strategies to effectively treat antibody-mediated rejection (AMR) are insufficient. Thus, we aimed to determine the benefit of a therapeutic protocol using bortezomib for refractory C4d + AMR in pediatric kidney transplant patients.Methods
We examined seven patients with treatment-refractory C4d + AMR. Immunosuppression included antithymocyte globulin or anti-CD25 monoclonal antibody for induction therapy with maintenance corticosteroids, calcineurin inhibitor, and anti-metabolite. Estimated glomerular filtration rate (eGFR) calculated by the Schwartz equation, biopsy findings assessed by 2013 Banff criteria, and human leukocyte antigen (HLA) donor-specific antibodies (DSA) performed using the Luminex single antigen bead assay were monitored pre- and post- bortezomib therapy.Results
Seven patients (86 % male, 86 % with ≥6/8 HLA mismatch, and 14 % with pre-formed DSA) age 5 to 19 (median 15) years developed refractory C4d + AMR between 1 and 145 (median 65) months post-transplantation. All patients tolerated bortezomib. One patient had allograft loss. Of the six patients with surviving grafts (86 %), mean pre-bortezomib eGFR was 42 ml/min/1.73 m2 and the mean 1 year post-bortezomib eGFR was 53 ml/min/1.73 m2. Five of seven (71 %) had improvement of histological findings of AMR, C4d staining, and/or acute cellular rejection. Reduction in HLA DSAs was more effective for class I than class II.Conclusions
Bortezomib appears safe and may correlate with stabilization of eGFR in pediatric kidney transplant patients with refractory C4d + AMR.108.
109.
Venous thromboembolism (VTE) is a significant healthcare burden with approximately 900,000 events annually in the United States, over half of which are healthcare-associated. This number is anticipated to double by 2050. Group prophylaxis strategies confined to the inpatient setting appear to have minimal impact on the reduction of post-discharge VTE in medically ill patients due to shortened lengths of stay and a heterogenous population that includes patients at low risk for VTE. In accordance with current guideline recommendations, very few (<5%) medically ill patients are discharged with extended prophylaxis, which potentially creates a clinical gap for at-risk patients as VTE risk has been shown to persist for up to 90 days. Initial studies of extended thromboprophylaxis in acutely ill medical patients with enoxaparin, rivaroxaban and apixaban showed little to no benefit towards VTE reduction that was consistently outweighed by increased bleeding. The more recent APEX study that compared betrixaban to enoxaparin in an enriched patient population at high-risk for VTE was the first study of extended thromboprophylaxis that showed similar efficacy in VTE prevention without an increase in major bleeding. Based on the APEX results, betrixaban recently gained FDA approval for extended thromboprophylaxis in acutely ill medical patients. Recognition that up to half of medically ill patients are not at sufficient risk to warrant thromboprophylaxis has driven extensive research towards development of scientifically derived and validated VTE risk assessment models intended to identify patients who do not warrant prophylaxis, as well as those at high risk who may derive benefit from extended thromboprophylaxis. This article will review prior and ongoing extended thromboprophylaxis studies, VTE and bleed risk assessment models, incorporation of biomarkers in VTE risk assessment and key issues in the paradigm shift towards individualized VTE prophylaxis in acutely ill medical patients. 相似文献
110.